BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21627301)

  • 1. Physicochemical conjugation with deoxycholic acid and dimethylsulfoxide for heparin oral delivery.
    Kim SK; Huh J; Kim SY; Byun Y; Lee DY; Moon HT
    Bioconjug Chem; 2011 Jul; 22(7):1451-8. PubMed ID: 21627301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation.
    Kim SK; Vaishali B; Lee E; Lee S; Lee YK; Kumar TS; Moon HT; Byun Y
    Thromb Res; 2006; 117(4):419-27. PubMed ID: 15913716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
    Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
    J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.
    Kim SK; Lee DY; Lee E; Lee YK; Kim CY; Moon HT; Byun Y
    J Control Release; 2007 Jul; 120(1-2):4-10. PubMed ID: 17490773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using a surface plasmon resonance.
    Kim SK; Kim K; Lee S; Park K; Park JH; Kwon IC; Choi K; Kim CY; Byun Y
    J Pharm Biomed Anal; 2005 Oct; 39(5):861-70. PubMed ID: 16143485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant efficacy of solid oral formulations containing a new heparin derivative.
    Park JW; Jeon OC; Kim SK; Al-Hilal TA; Moon HT; Kim CY; Byun Y
    Mol Pharm; 2010 Jun; 7(3):836-43. PubMed ID: 20349950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
    Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y
    J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of the GI tract by QDs loaded heparin-deoxycholic acid (DOCA) nanoparticles.
    Khatun Z; Nurunnabi M; Cho KJ; Lee YK
    Carbohydr Polym; 2012 Nov; 90(4):1461-8. PubMed ID: 22944403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
    Kim SK; Lee DY; Kim CY; Nam JH; Moon HT; Byun Y
    J Control Release; 2007 Nov; 123(2):155-63. PubMed ID: 17884230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates.
    Kim SK; Lee EH; Vaishali B; Lee S; Lee YK; Kim CY; Moon HT; Byun Y
    J Control Release; 2005 Jun; 105(1-2):32-42. PubMed ID: 15925422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant.
    Park JW; Jeon OC; Kim SK; Al-Hilal TA; Lim KM; Moon HT; Kim CY; Byun Y
    Thromb Haemost; 2011 Jun; 105(6):1060-71. PubMed ID: 21437357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention effect of orally active heparin derivative on deep vein thrombosis.
    Kim SK; Lee DY; Kim CY; Moon HT; Byun Y
    Thromb Haemost; 2006 Aug; 96(2):149-53. PubMed ID: 16894457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates.
    Park K; Kim K; Kwon IC; Kim SK; Lee S; Lee DY; Byun Y
    Langmuir; 2004 Dec; 20(26):11726-31. PubMed ID: 15595804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent.
    Lee Y; Nam JH; Shin HC; Byun Y
    Circulation; 2001 Dec; 104(25):3116-20. PubMed ID: 11748110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligomeric bile acid-mediated oral delivery of low molecular weight heparin.
    Al-Hilal TA; Park J; Alam F; Chung SW; Park JW; Kim K; Kwon IC; Kim IS; Kim SY; Byun Y
    J Control Release; 2014 Feb; 175():17-24. PubMed ID: 24333628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid.
    Alam F; Al-Hilal TA; Chung SW; Seo D; Mahmud F; Kim HS; Kim SY; Byun Y
    Biomaterials; 2014 Aug; 35(24):6543-52. PubMed ID: 24816287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral delivery of near-infrared quantum dot loaded micelles for noninvasive biomedical imaging.
    Khatun Z; Nurunnabi M; Cho KJ; Lee YK
    ACS Appl Mater Interfaces; 2012 Aug; 4(8):3880-7. PubMed ID: 22839507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral delivery of new heparin derivatives in rats.
    Lee Y; Kim SH; Byun Y
    Pharm Res; 2000 Oct; 17(10):1259-64. PubMed ID: 11145232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological properties of insulin-deoxycholic acid chemical conjugates.
    Lee S; Kim K; Kumar TS; Lee J; Kim SK; Lee DY; Lee YK; Byun Y
    Bioconjug Chem; 2005; 16(3):615-20. PubMed ID: 15898729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of sodium deoxycholate (DOC) conjugated heparin derivatives for inhibition of angiogenesis and cancer cell growth.
    Cho KJ; Moon HT; Park GE; Jeon OC; Byun Y; Lee YK
    Bioconjug Chem; 2008 Jul; 19(7):1346-51. PubMed ID: 18588324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.